Latest News
From the Journals
First prospective study finds pregnancies with Sjögren’s to be largely safe
There was no difference in risk of adverse pregnancy outcomes between women with Sjögren’s and the control group, but these negative outcomes were...
Feature
States move to curb insurers’ prior authorization requirements as federal reforms lag
Doctors and patients in several states would get some relief from burdensome prior authorization requirements if reform legislation becomes law....
From the Journals
Common fracture risk predictors often fail for women of any race
“What I hope this study does is to inform the next iteration of the screening guidelines,” by maintaining the recommendation to use the...
Feature
The weird world of hydrogels: How they’ll change health care
“As people develop new hydrogels that more closely match the tissues in our body, we’ll be able to treat a whole host of ailments we couldn’t...
Conference Coverage
Investigational lupus drug cenerimod moves to phase 3 studies after equivocal phase 2 results
Novel S1P1 receptor modulator cenerimod shows impact on disease activity in lupus, with more pronounced benefits in those with more severe disease...
Conference Coverage
Severe hydroxychloroquine nonadherence linked to worse SLE outcomes
Severe nonadherence to hydroxychloroquine in patients with lupus is associated with an increased risk of flare, organ damage, and mortality within...
Conference Coverage
AxSpA remission on TNFi seen in half of patients with comorbid IBD
Those who had IBD for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axSpA remission...
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
Latest News
Lupus landmark study aims for personalized medicine goals
The Lupus Landmark Study was designed as part of the Lupus Nexus, a combination registry, biorepository, and data portal.
Conference Coverage
AxSpA effects may be more severe for Black patients
A higher percentage of Black patients had elevated erythrocyte sedimentation rate, C-reactive protein, and hip involvement in a small study. Black...
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.